Short Interest in Jyong Biotech Ltd. (NASDAQ:MENS) Declines By 22.7%

Jyong Biotech Ltd. (NASDAQ:MENS) was the target of a large decrease in short interest in March. As of March 13th, there was short interest totaling 288,865 shares, a decrease of 22.7% from the February 26th total of 373,692 shares. Based on an average daily trading volume, of 210,084 shares, the short-interest ratio is currently 1.4 days. Approximately 0.4% of the company’s stock are sold short.

Jyong Biotech Price Performance

Shares of MENS stock traded down $0.04 during trading hours on Monday, hitting $1.90. The stock had a trading volume of 183,520 shares, compared to its average volume of 209,083. The stock’s 50 day moving average is $2.18 and its 200 day moving average is $22.36. Jyong Biotech has a twelve month low of $1.43 and a twelve month high of $67.00.

Jyong Biotech (NASDAQ:MENS) last announced its earnings results on Friday, January 9th. The company reported ($0.01) EPS for the quarter.

Hedge Funds Weigh In On Jyong Biotech

A number of hedge funds and other institutional investors have recently made changes to their positions in MENS. Jane Street Group LLC purchased a new stake in Jyong Biotech during the 4th quarter valued at approximately $275,000. Geode Capital Management LLC increased its holdings in shares of Jyong Biotech by 19.6% in the fourth quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock valued at $254,000 after purchasing an additional 10,538 shares during the period. Millennium Management LLC raised its stake in shares of Jyong Biotech by 209.4% during the fourth quarter. Millennium Management LLC now owns 40,258 shares of the company’s stock worth $159,000 after purchasing an additional 27,245 shares during the last quarter. Man Group plc acquired a new stake in shares of Jyong Biotech during the fourth quarter worth $56,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Jyong Biotech in the 4th quarter valued at $49,000.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.